Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
dopamine receptor antagonist |
| gptkbp:CASNumber |
82030-01-3
|
| gptkbp:hasInChIKey |
QXQNVJQVAABRRO-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C17H18ClNO
|
| gptkbp:hasSMILES |
CC1=C(C2=C(C=C(C=C2)O)N(C3=CC=CC=C3)CC1)Cl
|
| gptkbp:hasUNII |
6LR8C1B12V
|
| https://www.w3.org/2000/01/rdf-schema#label |
SCH23390
|
| gptkbp:is_not_approved_for |
clinical use
|
| gptkbp:is_selective_for |
gptkb:dopamine_D1_receptor
|
| gptkbp:IUPACName |
7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol
|
| gptkbp:meltingPoint |
220-222°C
|
| gptkbp:PubChem_CID |
5217
5029 CHEMBL32537 |
| gptkbp:synonym |
R-(+)-SCH23390
R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| gptkbp:target |
gptkb:dopamine_D1_receptor
|
| gptkbp:used_in |
scientific research
|
| gptkbp:was_developed_by |
gptkb:Schering-Plough
|
| gptkbp:bfsParent |
gptkb:dopamine_receptor_D1
gptkb:dopamine_receptor_D5 |
| gptkbp:bfsLayer |
7
|